A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
Here, the investigators present the results from a Phase Ib/II study of PM8002 in combination with nab-paclitaxel in subjects with locally advanced or metastatic triple negative breast cancer without previous systematic treatment.